



PReDICT: Pediatric stroke Rare Disorders Integrative Diagnosis and Treatment using Multi-Omics and Deep Learning

Cristòfol Vives-Bauzà

Damià Heine Suñer

13 de Junio de 2025



PReDICT



PReDICT Consortium



HUCA-Asturias
Dra. Raquel Blanco Lago



HU. de Burgos
Dr. Juan Arnáez



IIS-Biogipuzkoa- Osakidetza
Dra. Itxaso Martí
Dra. Patricia de la Riva



Navarrabiomed-HU. Navarra
Dr. Sergio Aguilera



IRB-Lleida-H. Arnau Vilanova
Dr. Francisco Purroy
Dra. Gloria Arqué



VHIR-H. Vall d'Hebrón
Dra. Belén Pérez
Dra. Anna Rosell




IIS-Sant Pau
H. Santa Creu i Sant Pau
Dra. Eulalia Turón
Dra. Cristina Gallego



IdISBa- HU. Son Espases
Dr. Damià Heine
Dr. Cristòfol Vives



IIS La Fe-H. U. La Fe
Dr. Juan B. Salom



SESCAM-CHU. Albacete
Dra. Maria C. Carrascosa
Dra. Gemma Serrano-Heras



IDIS-SERGAS
Dr. Francisco Campos




IdIPAZ-H. U. La Paz
Dra. Cristina Barcia



IISGM- H. Gregorio Marañón
Dra. María Vázquez




IBIS-Hospital U. Virgen Macarena
Dra. Ana M. Domínguez
Dr. Joan Montaner





Several Rare Diseases Present with Stroke in Children




2024

CONVOCATORIA MISIONES CONJUNTAS PARA CONCESION DE SUBVENCIONES A PROYECTOS DE INVESTIGACION EN ENFERMEDADES RARAS



Pediatric Stroke causes Long-Term Neurological Deficits in Infants




Perinatal stroke

From the 20th week of gestation until the 28th day after birth

Leading cause of hemiparetic cerebral palsy and lifelong impacts including motor, cognitive and epileptic issues



Pediatric Stroke causes Long-Term Neurological Deficits in Infants



Perinatal stroke

From the 20th week of gestation until the 28th day after birth

Leading cause of hemiparetic cerebral palsy and lifelong impacts including motor, cognitive and epileptic issues




Incidence

- 25 to 40 per 100,000 in neonates
- 100 per 100,000 in premature neonates



Pediatric Stroke Risk Factors




(Janckovic et al. 2021)



Mapping the genetic architecture of pediatric stroke

(Malone et al. 2020; Lynch et al. 2022)

PReDICT: Pediatric stroke Rare Disorders: Integrative Diagnosis and Treatment using Multi-Omics and Deep Learning





WP1. Clinical Outcomes of Pediatric Stroke Patients (following COSMIN guidelines)



Dra. Ana M. Domínguez



CLINICAL VARIABLES:

Global Performance: Pediatric Stroke Outcome Measure (PSOM) and Pediatric Stroke Recurrence and Recovery Questionnaire (psRRQ)

Motor Function: Gross Motor Functional Measure (GMFM)

Adaptive Functioning and Behavior: Child and Adolescent Scale of Participation (CASP)

Quality of Life: Pediatric Stroke Quality of Life Measure (PSQLM)

Mood: Revised Children's Anxiety and Depression Scale (RCADS)

Cognition: NIH Toolbox

Memory: California Verbal Learning Test (CVLT-C)

Executive Function: Behavior Rating Inventory of Executive Function


Speech and Language: Focus on the Outcome of Communication Under Six

DEMOGRAPHIC VARIABLES: Prematurity, primiparity, birth weight, cardiac disorders, congenital thrombophilia, infections, maternal diseases and cigarette smoking, placental disorders, occurrence of birth asphyxia, APGAR score.





WP2. Neuroimaging Analysis: Connectome's signature associated with Pediatric Stroke




Dr. Francisco Purroy
Dra. Gloria Arqué



WP3. Trio-WGS and RNASeq to identify rare bi-allelic and *de novo* variants, CNVs, and regulatory non-coding variants as a cause of Pediatric Stroke.

PR_eDICT



- Variant calls
- Filter by frequency
- Filter by functional impact
- Filter by inheritance pattern

Dr. Damià Heine-Suñer





Trio-Exome Sequencing for Variant Analysis

Whole Exome Sequencing (WES)







Image source: Sanju Tamang, 2024



Trio-Exome Sequencing for Variant Analysis

Whole Exome Sequencing (WES)



Advantages of trio-exome sequencing:

- *De novo* variants
- Recessive compound
- Inherited pathogenic variants

Image source: Sanju Tamang, 2024



Pilot Study: Cohort of 34 Patients

H. Virgen Macarena & H. Son Espases

	Haemorrhagic		Ischemic		
	ICH/IVH	SAH	AIS	CSVT	<i>Total</i>
Perinatal					
Acute PS	6	4	6	-	
Presumed PS	-	2	10	-	
Postnatal	-	-	4	2	
<i>Males</i>	5	3	8	1	17
<i>Females</i>	1	3	12	1	17
<i>Total</i>	6	6	20	2	N = 34





Variant Analysis Using Virtual Genomic Panels



Bleeding disorders
(e.g., F7, F13A1)



Cerebral vascular malformations
(e.g., ACVRL1, CCM2)



Ischemic stroke risk
(e.g., PDE4D, NOTCH3)



Vascular development
(e.g. NOTCH1, TGFBR2)




Vascular structure: cell polarity, cell-cell and cell-matrix interactions
(e.g. JAM3, PECAM1, COL1A1)



Variants with global allele frequency $<1\%$




Almost 70% of Patients Harbored Pathogenic or Likely Pathogenic Rare Variants





Almost 70% of Patients Harbored Pathogenic or Likely Pathogenic Rare Variants





19 Genes Harboring Inherited Variants


Gene	Main Associated disorders
AARS1	Charcot-Marie-Tooth Disease Type 2N and Leukoencephalopathy
ABCC6	Pseudoxanthoma Elasticum
ABCC8	Diabetes Mellitus, Hyperinsulinemic Hypoglycemia familial
APOB	Familial Hypercholesterolemia
ATM	Ataxia-Telangiectasia syndrome
F11	Factor XI deficiency
GP1BA	Bernard-Soulier Syndrome
HPS6	Hermansky-Pudlak Syndrome
INSR	Donohue Syndrome (Severe Insulin Resistance)
JAG1	Alagille syndrome

Gene	Main Associated disorders
KCNH2	Long QT Syndrome Type 2
KCNMA1	Epilepsy, Paroxysmal Dyskinesia and Liang-Wang syndrome
MPZ	Charcot-Marie-Tooth Disease Type 1B
NDUFAF7	Leigh Syndrome (Mitochondrial Complex I Deficiency)
ROBO4	Aortic Valve Disease 3 and Ascending Aortic Aneurysm
RP1	Retinitis Pigmentosa
SCN3A	Developmental and epileptic encephalopathy
SERPINC1	Antithrombin III Deficiency
SLC5A2	Renal glucosuria



3 Genes Harboring Biallelic Recessive Variants

Gene	Main Associated disorders
ASPM	Microcephaly, Lissencephaly, various cancers
EPRS1	Leukodystrophy, Microcephaly with Seizures And Cerebral And Cerebellar Atrophy
HPS1	Hermansky-Pudlak Syndrome





9 Genes Harboring *de Novo* Variants

Gene	Main Associated disorders
CBL	Juvenile myelomonocytic leukemia (JMML), Moyamoya Syndrome
TIE1	Angiosarcoma, Inflammatory Breast Carcinoma
TCF12	Craniosynostosis, Intellectual Disability, Skeletal Development Syndromes
NF1	Neurofibromatosis type 1 (NF1), Juvenile Myelomonocytic Leukaemia
SEMA5A	Cri-Du-Chat Syndrome, Autism spectrum disorder (ASD), various cancers
KAT6A	Arboleda-Tham Syndrome, Syndromic Intellectual Disability
CAMK2A	Intellectual Developmental Disorder, Cortical Dysplasia With Other Brain Malformations
ENC1	Sandhoff Disease, Neuroblastoma, various cancers
RPA1	Disorders of DNA Repair (non-specific)

(NCBI Gene, GeneCards)




de Novo Rare Variants



RELATED TO STROKE RISK AND VASCULAR MALFORMATIONS



Gene	Functional effect of the mutation	Function	Main Associated Pathologies (non-stroke)	Potential Link to Arterial Ischemic Stroke (AIS)	Source
NF1 (Neurofibromin 1)	missense	Ras-GAP protein; tumour suppressor controlling cell growth/differentiation.	Neurofibromatosis type 1 (NF1), juvenile myelomonocytic leukaemia, Watson syndrome, gliomas and learning disabilities	As a RASopathy can affect the vascular formation and influence various cellular processes that determine the brain injury	PMID: 12432832 ; PMC11303248 ; PMC5873857





de Novo Rare Variants




RELATED TO VASCULAR DEVELOPMENT

Gene	Functional effect of the mutation	Function	Main Associated Pathologies (non-stroke)	Potential Link to Arterial Ischemic Stroke (AIS)	Source
SEMA5A (Semaphorin 5A)	missense	Semaphorin family guidance cue; roles in axon guidance, angiogenesis and cell migration	Cri-Du-Chat Syndrome, Autism spectrum disorder (ASD), cancers (lung, pancreas)	Contributes to the remodelling of cranial blood vessels and the progression of stroke	PMC486745; PMC8957939; PMID: 25651171; PMC1061610; PMID: 38548715

a

Sema5A






de Novo Rare Variants



RELATED TO VASCULAR DEVELOPMENT

Gene	Functional effect of the mutation	Function	Main Associated Pathologies (non-stroke)	Potential Link to Arterial Ischemic Stroke (AIS)	Source
TIE1 (Tyrosine kinase with immunoglobulin-like and EGF-like domains 1)	missense	Endothelial receptor kinase involved in angiogenesis and vessel stability	Angiosarcoma, Inflammatory Breast Carcinoma, Malignant Renovascular Hypertension	Impairment of endothelial stability and cerebrovascular maturation	PMID: 38820174 PMC9508414 PMC6309948



PMID: 26344773

TAKE-HOME MESSAGES



Perinatal stroke results from a broader spectrum of genetic abnormalities than previously thought


Trio-exome sequencing was highly effective in diagnosing pediatric stroke



Need for deeper investigation into rare genetic contributors to stroke



WP4. 3D-models of NVU-derived from patients to confirm variant's pathogenicity and to model BBB dysfunction, Inflammation & Angiogenesis



Dr. Francisco Campos



INSTITUTO DE INVESTIGACIÓN SANITARIA
SANTIAGO DE COMPOSTELA



Dra. Anna Rosell



Dr. Juan B. Salom




Dr. Cristòfol Vives





3D models of brain capillary beds





The diagram is divided into two parts by a vertical line. The left part shows a medical procedure: a person's forearm is shown with a blue bandage securing a needle. A tube connected to the needle is filled with red blood cells, representing a blood sample. The right part shows a histological cross-section of skin. The skin layers are depicted with various colors: the epidermis is pink with wavy lines, the dermis is light pink with wavy lines and small dark spots, and the subcutaneous layer is yellow with a honeycomb pattern.

PBS/EDTA

Dilution


Collect PBMCs

Cultured fibroblasts from skin biopsy

The diagram is divided into two panels. The left panel, titled 'Sendai virus vector', shows a cell with a Sendai virus particle entering the cytoplasm. The virus replicates and transcribes its genome in the cytoplasm, producing NP, P, and L proteins. The NP protein enters the nucleus, where the target protein gene is located. The NP protein then moves back to the cytoplasm, where it facilitates the replication and transcription of the target protein gene. The resulting target protein is then transported into the endoplasmic reticulum (ER) and Golgi apparatus (GA) for secretion. The right panel, titled 'Other vectors', shows a cell with a target protein gene in the nucleus. The gene is transcribed into mRNA, which is then translated into the target protein in the cytoplasm. The target protein is then transported into the ER and Golgi apparatus for secretion.



The diagram illustrates the differentiation protocol for hiPSCs. It begins with **hiPSCs** (green cells). The process follows these steps:

- Day -2/0**: **hiPSC Passaging and Maintenance**. This step involves passaging the cells into a well.
- Day 0-5**: **Differentiate hiPSCs to vascular cells**. The cells are differentiated into a mixture of **Pericytes** (yellow cells) and **Endothelial Progenitor Cells** (red cells).
- Day 6**: **CD34 Magnetic-activated Cell Sorting (MACS)**. The cells are sorted based on CD34 expression.
 - CD34- Fraction**: This fraction is used for **Differentiate and Expand** to produce **Pericytes**.
 - CD34+ Fraction**: This fraction is used to isolate **Endothelial Progenitor Cells**, which are then **Expand & Freeze** for future use.









ICH associated with a biallelic recessive nonsense variant in the ESAM gene






Generation of iPSCs from Skin Fibroblasts of two siblings harboring a biallelic recessive nonsense variant in the *ESAM* gene



Dr. Ana Bugalló
IDIS



Dr. Tania García
IdISBa-HUSE




Denise G. Gornatti
IdISBa-HUSE






Differentiation of iPSCs to Endothelial Cells and Pericytes





Brain endothelial cells, astrocytes, and neurons in a 3D NVU on-a-chip





Thanks for your attention!



cristofol.vives@uib.cat
damia.heine@ssib.es